This is a working overview of carcinogenicity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Specific plan elements included defense and non-defense spending freezes for 4–5 years, income tax reform, elimination of tax expenditures, and a national sales tax or value-added tax (VAT). The Hamilton Project published a guidebook with 15 different proposals from various policy and budget experts in February, 2013. The authors were asked to provide pragmatic, evidenced-based proposals that would both reduce the deficit and bring broader economic benefits. Proposals included a value added tax and reductions to tax expenditures, among others.
It was not until he [Trask] had exercised for some time that he could perform any labor ... [H]is neck and back have continued to curve drawing his head downward on his breast. The account of Trask became the first documented case of AS in the United States, owing to its indisputable description of inflammatory disease characteristics of AS and the hallmark of deforming injury in AS. In the late nineteenth century, the neurophysiologist Vladimir Bekhterev of Russia in 1893, Adolf Strümpell of Germany in 1897, and Pierre Marie of France in 1898 were the first to give adequate descriptions which permitted an accurate diagnosis of AS prior to severe spinal deformity. For this reason, AS is also known as Bekhterev disease, Bechterew's disease or Marie–Strümpell disease. The word is from Greek ankylos meaning crooked, curved or rounded, spondylos meaning vertebra, and -itis meaning inflammation.
== Sources == This article incorporates text from a free content work. Licensed under CC BY 4.0. Text taken from The State of Food Security and Nutrition in the World 2024, FAO, IFAD, UNICEF, WFP and WHO, FAO. This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2026, Food and Agriculture Organization of the United Nations.
S0 + hν → S1 S1 + S1 → S0 + Sn S1 + Sn → M+ + M− where S0 is the ground electronic state, S1 the first electronic excited state, and Sn is a higher electronic excited state. The product ions can be proton transfer or electron transfer ion pairs, indicated by M+ and M− above. Secondary processes involve ion-molecule reactions to form analyte ions.
Sources: en.wikipedia.org
Ceremonial San Pedro use seems to be characterized by relatively strong spiritual experiences, and low incidence of challenging experiences. DMT (N,N-dimethyltryptamine) is an indole alkaloid found in various species of plants. Traditionally, it is consumed by tribes in South America in the form of ayahuasca. A brew is used that consists of DMT-containing plants as well as plants containing monoamine oxidase inhibitors (MAOIs), like harmine and harmaline, which allows DMT to be consumed orally without being rendered inactive by monoamine oxidase (MAO) enzymes in the digestive system. A pharmaceutical version of ayahuasca is called pharmahuasca. In the Western world, DMT is more commonly consumed via the vaporisation of freebase DMT. Whereas ayahuasca typically lasts for several hours, inhalation has an onset measured in seconds and has effects measured in minutes, being much more intense. Particularly in smoked or vaporised form, DMT has the ability to cause users to enter a hallucinatory realm fully detached from reality, being typically characterised by hyperbolic geometry, and described as defying visual or verbal description. Users have also reported encountering and communicating with entities within this hallucinatory state. DMT is the archetypal substituted tryptamine, being the structural scaffold of psilocybin and, to a lesser extent, the lysergamides. 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine; mebufotenin) is a naturally occurring substituted 5-methoxytryptamine which was first identified as having psychedelic effects in the 1960s.
Attempted trafficking and complicity in attempted trafficking in Thymosin Beta-4, Hexarelin and Humanofort to Essendon in 2012 Trafficking in Mechano Growth Factor to a support staff member of the Carlton Football Club in 2012 Attempted trafficking and complicity in attempted trafficking in CJC-1295 to the Gold Coast Football Club in 2010 Trafficking in GHRP-6 and complicity in attempted trafficking in Hexarelin, SARMS, CJC-1295 and GHRP6 to a baseball club in 2012 Trafficking in GHRP6 and Mechano Growth Factor to the Medical Rejuvenation Clinic in 2011–2012. The AFL suspended Dank from involvement in the sport for life. Since most Australian sporting organisations honour sanctions imposed by other leagues, this effectively blackballed Dank from major Australian sport. Dank was found not guilty of twenty-one other charges, including trafficking charges and all charges related to administering the supplements. Dank appealed the ten guilty verdicts, but the appeals were dismissed after he failed to attend his session with the AFL appeals board in November 2016. WADA lodged an appeal against the twenty-one not guilty verdicts in June 2015.
=== Nanomedicine (nanotheranostics) === Nanomedicine refers to the use of nanoscale materials for medical applications. In theranostics, nanomedicine offers opportunities for targeted drug delivery, imaging, and therapy. Nanoparticles can be engineered to carry therapeutic payloads, imaging agents, and targeting ligands, allowing for multimodal theranostic approaches. These nanocarriers can enhance drug stability, improve drug solubility, and enable controlled release at the disease site. Additionally, nanomaterials with inherent imaging properties, such as quantum dots or gold nanoparticles, can serve as contrast agents for imaging.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.